Abstract
Tissue-engineered products are being developed in experimental laboratories worldwide and will be available for the treatment of several diseases in the near future. The Japanese Ministry of Health and Welfare (MHW) has no guidelines for preclinical studies and clinical investigations of tissue-engineered products at the present time. In this paper, the future problems and current policies concerning the safety and effectiveness of tissue-engineered products are described.
Get full access to this article
View all access options for this article.